Eli Lilly is expected to announce Tuesday that its late-breaking combination therapy trial data — presented to considerable attention at the American Academy of Dermatology (AAD) 2026 Annual Meeting — has been formally submitted for publication in the New England Journal of Medicine, as the conference concludes in San Diego. The study, which demonstrated statistically significant improvements in joint inflammation scores alongside meaningful reductions in body weight among psoriatic arthritis patients with comorbid obesity, drew standing-room audiences during the meeting's final sessions.

The trial paired Lilly's IL-17 inhibitor ixekizumab with its GLP-1 receptor agonist tirzepatide, targeting the well-documented overlap between systemic inflammation and metabolic dysfunction in psoriatic arthritis patients. Investigators reported that patients on the combination regimen achieved ACR50 response rates roughly 18 percentage points higher than those on either monotherapy alone, while also shedding an average of 11 percent of baseline body weight over 52 weeks.

Sun Pharma, which is also spotlighting 14 dermatology studies at the same AAD gathering, acknowledged the Lilly data as 'a pivotal moment for the field,' according to remarks attributed to its medical affairs team. Analysts at SVB Securities noted that a positive NEJM publication timeline could accelerate Lilly's supplemental FDA submission for the combination indication, with a potential filing window opening as early as Q3 2026.

The AAD meeting, which attracted more than 18,000 dermatologists and rheumatologists from over 90 countries, closes Tuesday with a plenary session focused on biologics and small-molecule therapies. Lilly executives are scheduled to hold a press briefing at 10 a.m. Pacific time to address the trial findings and outline the regulatory pathway ahead.

Investors reacted cautiously ahead of the formal announcement, with Lilly shares trading up 1.4 percent in pre-market activity on Monday. Competing IL-17 and IL-23 manufacturers, including AbbVie and UCB, are expected to issue statements responding to the data as the market digests the potential competitive implications for the estimated $12 billion global psoriatic arthritis treatment market.